25/08/2026
Hadassah participated in an oncology trial whose results have stunned the medical world!
Moderna and Merck have reported that, for the first time, a personalized mRNA-based neoantigen therapy has demonstrated positive, statistically significant results in a Phase 3 clinical trial. Hadassah, a global leader in personalized cancer treatment, was among the medical centers that participated in the trial.
“Patients from our Sharett Institute of Oncology who were diagnosed with melanoma took part in this international trial”, says Dr. Jonathan Cohen, Director of the Oncology Clinical Trials Unit at Hadassah. “Unlike vaccines against COVID-19, this treatment targets cancer cells that originate within the body rather than an external pathogen. This presents a significant challenge: the immune system must recognize the cancer as foreign without attacking healthy cells. Achieving this requires a level of personalized medicine that, until now, the medical world has not been able to provide”.
“The treatment works by genetically sequencing a sample of each patient’s tumor and identifying its unique mutations by comparing them with the genome of healthy blood cells from the same patient. The vaccine is not an off-the-shelf product. It is individually manufactured for each patient through a process that requires the transatlantic shipment of samples, extensive laboratory work, and the subsequent production and shipment of the personalized treatment back to the patient, all on a large scale”, explains Dr. Cohen.
“Here at Hadassah, we are now recruiting patients to receive treatments based on the same approach for lung cancer, as well as patients with metastatic melanoma who have not yet received treatment for their disease. Similar vaccines are being studied across a range of other cancer types, and we hope that these treatments will also become available to our patients at Hadassah in the future”.